Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance [Yahoo! Finance]
LeMaitre Vascular, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions [Yahoo! Finance]
LeMaitre Vascular First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
LeMaitre Vascular, Inc. (NASDAQ: LMAT) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) had its price target raised by analysts at JMP Securities from $72.00 to $77.00. They now have a "market outperform" rating on the stock.